Many of the American Society of Hematology (ASH) presentations in Myeloma included information about Daratumumab. We covered some of the findings in an earlier article about the Griffin study and daratumumab with weekly carfilzomib. Dr. Robert Rifkin joined the Myeloma Crowd at ASH to share a new combination for daratumumab that does NOT include an [...]
This post first appeared on Page Not Found - The Myeloma Crowd, please read the originial post: here
